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Intestinal peptide transporters, including hPEPT1, facili-
tate the absorption of cephalosporins and angiotensin-
converting enzyme inhibitors, and have been investigated 
as a means to improve oral drug absorption. Renal peptide 
transporters including hPEPT2, may also facilitate renal 
reabsorption of such compounds. In vitro and animal 
studies suggest that co-administration of peptidomimetic 
compounds may alter oral pharmacokinetics, although 
this has not been well studied in humans. The purpose of 
this study was to determine whether co-administration of 
the hPEPT substrates captopril and cephradine alters the 
oral pharmacokinetics of either agent. Nine healthy male 
volunteers received a single oral 25-mg dose of captopril, 
a single oral 500-mg dose of cephradine, or concurrent 
ingestion of captopril and cephradine in a cross-over man-
ner. Venous blood samples were taken and captopril and 
cephradine pharmacokinetics were determined using non-
compartmental analyses. No significant differences were 
observed in captopril or cephradine pharmacokinetics 
when administered together as compared to each agent 
alone (a marginal decrease in Cmax was observed for both 
captopril and cephradine during co-administration [5–15%]; 
however, differences were not statistically significant). The 
results of our study suggest that hPEPT1 and hPEPT2 are 
unlikely to contribute to clinically important drug interac-
tions in humans.
Keywords:  Cephalosporin; ACE-inhibitor; peptide trans-
port; drug interaction; hPEPT1
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The disposition of many xenobiotics is highly dependent on the activity of intestinal mucosal 
transporters.1 Efflux transporters have been studied 
extensively, and can limit the systemic availability 
of a large range of compounds.2,3 In contrast, the role 
of nutrient transporters in facilitating drug absorp-
tion and tissue delivery has been investigated less 
comprehensively. It is well recognized, however, 
that multiple nutrient transporter systems involved 
in the active absorption of peptides, glucose and 
other carbohydrates, amino acids, organic anions, 
organic cations, bile acids, and other nutrients are 
abundant in the intestinal mucosa, and that many of 
these transporters may also affect the absorption of 
exogenously administered xenobiotics.1,4–6
In the small intestine, di- and tripeptides are 
absorbed through carrier-mediated processes by pep-
tide transporters, including the human oligopeptide 
transporter, hPEPT1 (SLC15A1). hPEPT1 is an H+/
peptide symporter located in the brush border mem-
brane of the small intestine which has broad sub-
strate specificity.1,7,8 In addition to transporting 
oligopeptides, hPEPT1 also mediates the membrane 
transport of a diverse range of xenobiotics, including 
peptidomimetic drugs. Substrates for hPEPT1 
include β-lactam antibiotics, aminocephalosporins 
with a free α-amino group, antiviral prodrugs (eg, 
valacyclovir, valgancyclovir), and angiotensin- 
converting enzyme (ACE) inhibitors.8–10 Peptide 
transporters are also present in other organs such as 
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the kidneys, central nervous system, and respiratory 
tract.11–13 The presence of hPEPT1 and the related 
renal oligopeptide transporter, hPEPT2, in the 
kidneys may play a role in the renal reabsorption of 
peptidomimetics.14–16
Drug interactions occurring as a result of co- 
administration of hPEPT1 substrates in humans are 
not well studied. These interactions are of interest, 
because there are a large number of hPEPT1 drug 
substrates, and hPEPT1 is actively targeted as a 
means to improve oral drug absorption. Therefore, it 
would be desirable if co-administration of hPEPT1 
substrates did not result in interactions. However, 
co-administration of transporter substrates may 
result in competition for transporters, and could 
affect the intestinal absorption and disposition of 
the substrates. To this end, competitive inhibition of 
hPEPT1-mediated transport of substrates, including 
cephalosporin antibiotics and ACE inhibitors, has 
been described in cultured epithelial cell models, 
excised membrane vesicles, and in situ animal 
models.17–28 Similarly, competitive inhibition of pep-
tide transport has been demonstrated in renal brush 
border membrane vesicles, and suggested in animal 
models.15 Based on these data, one may anticipate 
that drug–drug and/or drug–nutrient interactions 
involving peptide transporters are possible in 
humans. The purpose of this study was to assess the 
potential interaction between 2 peptidomimetic 
hPEPT1 substrates, the aminocephalosporin cephra-
dine, and the ACE inhibitor captopril, in humans. 
Specifically, we hypothesized that competition of 
captopril and cephradine for intestinal transporters 
may result in impaired and/or delayed absorption of 
either or both agents.
METHODS
Human Subjects
Nine healthy male volunteers were included in this 
study. Subjects were deemed healthy by physical 
examination and serum chemistries. The mean weight 
of the subjects was 75 kg (range, 64–91 kg), and all 
subjects were within 20% of their ideal body weight. 
The mean age of the subjects was 26 years (range, 
20–32 years). All subjects were nonsmokers, had 
refrained from other medications (prescription and 
over-the-counter) for 1 week before study entry, and 
had no history of hypersensitivity to cephalosporins or 
ACE inhibitors. All subjects provided written informed 
consent before participation, and all procedures were 
approved by the University of Michigan Institutional 
Review Board before initiating the study.
A randomized, open label, 3-way, cross-over 
design was used. The 3 study phases consisted of: 
(1) Phase A: a single 25-mg oral dose of captopril 
(Capoten, Bristol-Myers Squibb, New York, NY); 
(2) Phase B: a 500-mg oral dose of cephradine 
(Velosef, Bristol-Myers Squibb, New York, NY) co-
administered with a 25-mg oral dose of captopril, 
and (3) Phase C: a single 500-mg oral dose of cephra-
dine. All medications were from the same lot. In 
each phase, subjects were instructed to fast over-
night (approximately 10 hours) before oral adminis-
tration of the assigned study drug treatment, which 
was administered with 240 mL of water. During each 
phase, subjects were required to remain in a sitting 
position for 4 hours after receiving the study medi-
cation. Each study phase was separated by a mini-
mum of 2 weeks. Standard meals were provided 4 
and 9 hours after dosing. Venous blood samples (10 
mL) were collected immediately before dosing, and 
at 0.25. 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 9, and 
10 hours after drug administration during each treat-
ment phase. Samples were centrifuged at 4οC, and 
the plasma samples for captopril assays were treated 
with excess n-ethylmaleimide (NEM) to form a sta-
ble captopril-NEM adduct and then stored at -20οC 
until time of analysis.
Analytical Methods
After an oral dose, captopril is present in the plasma 
as unchanged drug (approximately 50% of dose) 
and a dimeric disulfide metabolite (approximately 
10% of dose). Therefore, plasma concentrations of 
both total and unchanged captopril were deter-
mined as described previously, with some minor 
modifications.29,30 In brief, the 4-ethoxy proline ana-
logue of captopril served as the internal standard. 
After extracting the excess NEM with 5 mL of ethyl 
acetate, the aqueous phase was acidified with 500 
µL of 2M HCl, to which 2 g of sodium chloride was 
added, vortexed and extracted with 10 mL of puri-
fied ethyl acetate. The ethyl acetate layer was evapo-
rated to dryness under nitrogen in a 40–50οC water 
bath. The dry extract was treated with 100 µL of 
hexafluoro-2-propanol and 50 µL of trifluoroacetic 
anhydride for 15 minutes at 60οC, evaporated under 
N2 and the dry residue reconstituted with ethylace-
tate: N-methyl formamide (1:1). An aliquot contain-
ing the hexafluorisopropyl esters of the NEM adducts 
of captopril and the internal standard was injected 
into a gas chromatography-mass spectrophotometer 
assembly. To determine total captopril content, trib-
utylphosphine (20% v/v) was added to the plasma 
samples, vortexed and heated for 60 minutes at 50οC. 
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Excess tributylphosphine was extracted with 5 mL 
of ethyl acetate. Subsequently 0.2 mL of NEM (10 
mg/mL) was added to the aqueous plasma layer 
which was then allowed to stand for 15 minutes at 
room temperature. Further extraction, derivatization 
and GC analysis were performed as outlined for 
unchanged captopril. Standard curves were pre-
pared daily and constructed from spiked blank 
plasma containing 0–500 ng/mL of captopril, 500 ng 
of internal standard and 100 µL of NEM. For this 
assay, the lower limit of detection of captopril in 
plasma was 2 ng/mL, and the inter-day coefficient of 
variation was 7%.
Cephradine concentrations were determined 
using high-performance liquid chromatography 
using methods adapted from Lidgren and col-
leagues.31 Briefly, the analytical column was a 
µBondpak C18 column, the mobile phase was 13% 
acetonitrile in 0.02 M NaH2PO4 (pH 5), the flow rate 
of the mobile phase was 1.6 mL/min, and absorb-
ance was measured at 262 nm. For the cepharadine 
assay, the intra-day coefficient of variation for the 
assay was <6% over the concentration range of 3 to 
20 µg/mL, and the inter-day coefficient of variation 
was <5% over the same concentration range.
Pharmacokinetic Analysis
Conventional noncompartmental pharmacokinetic 
analyses were performed.32 Maximum plasma con-
centration (Cmax), and time to maximum plasma con-
centration (Tmax), were determined by visual 
inspection of the data. The apparent elimination 
constant (ke) was calculated based on linear regres-
sion of the log-linear terminal phase of the plasma 
concentration time curve. Elimination half-life was 
determined as (ln 2/ke). The area under the plasma 
concentration versus time curve (AUCinf) was calcu-
lated using the trapezoidal rule and extrapolated to 
infinity based on Cn/ke, were Cn is the last measure-
able concentration. Additionally, partial areas under 
the plasma concentration versus time curve in the 
first hour after administration (AUC0–1) were calcu-
lated to better characterize changes in absorption (ie, 
while absorption was the dominant process).
Statistical Analyses
Statistical analyses were performed to explore poten-
tial differences in pharmacokinetic parameters between 
study phases using 2-tailed, paired t tests. Data are 
presented as mean ± standard deviation (SD). For all 
tests, P < .05 was considered to be significant.
RESULTS
Noncompartmental Analyses
Mean plasma concentrations of unchanged and total 
captopril versus time curves after oral administra-
tion of captopril alone or after co-administration of 
cephradine with captopril to human subjects are 
shown in Figure 1. The relevant pharmacokinetic 
parameters for unchanged and total captopril during 
phase A (captopril alone) and Phase B (captopril co-
administered with cephradine) are summarized in 
Table I. No significant differences were noted in the 
pharmacokinetics of either unchanged or total cap-
topril when administered alone or in combination 
with cephradine. Of interest, the Cmax for both 
unchanged and total captopril was slightly decreased 
when captopril was co-administered with cephra-
dine as compared to when it was administered alone 
and likewise the Tmax was slightly delayed. Detectible 
total captopril concentrations were still present at 
the end of the sampling (10 hours); our sampling 
strategy captured 89.1% of the mean AUC0–infinity 
for total captopril alone, and 88.1% of the mean 
AUC0–infinity for total captopril with cephradine.
Cephradine mean plasma concentration versus 
time curves are similar after oral administration of 
cephradine alone or after co-administration of cephra-
dine with captopril (Figure 2). The pharmacokinetic 
parameters for cephradine when administered alone 
Figure 1.  Captopril unchanged and total captopril plasma con-
centration versus time curves. Data represent mean ± SD for each 
time point. , captopril alone; , captopril with cephradine.
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(phase C) or in combination with captopril are listed 
in Table II. Captopril administration resulted in a 
marginal decrease in the Cmax of cephradine; the 
mean percent decrease in Cmax was 10.0 ± 15.6, 
although this difference only approached signifi-
cance (P = .053). Figure 3 shows the effects of 
captopril administration on cephradine Cmax for 
individual subjects. In 6 of the 9 subjects, captopril 
administration was associated with a decrease in 
cephradine Cmax, whereas cephradine Cmax was higher 
with co-administration of captopril in 3 subjects. 
Co-administration of captopril did not significantly 
delay cephradine absorption, nor did it significantly 
impair the extent of cephradine absorption, as indi-
cated by Tmax, f (0–1), and AUCinf values (Table II). 
DISCUSSION
The oligopeptide transporter hPEPT1 plays a role in 
the active absorption of several drugs, and has been 
suggested as a potential means to improve the oral 
absorption of drugs in the drug design process. 
Despite the pharmacological importance of hPEPT1, 
little is known about the propensity of hPEPT1 (and 
the related renal transporter, hPEPT2) to cause drug 
interactions in humans. In this study, we observed 
no clinically significant interaction when 2 peptido-
mimetic substrates, captopril and cephradine, were 
co-administered to healthy human subjects by means 
of the oral route. Co-administration slightly decreased 
the mean peak plasma concentration of cephradine, 
however, this difference only approached statistical 
significance. Although this could indicate competi-
tion for uptake by peptide transporters in the intes-
tine, no other pharmacokinetic parameters supported 
such an interaction; specifically, no significant 
changes in Tmax, AUCinf, or partial AUC’s were 
observed with captopril co-administration. Both 
captopril and cephradine are eliminated, at least in 
Table I  Total Captopril and Unchanged Captopril Pharmacokinetic Parameters  
From Noncompartmental Analysisa
 Parameter Captopril Alone Captopril with Cephradine
Unchanged captopril Cmax (ng/mL)  177.3 ± 46.8 153.0 ± 48.0
 Tmax (h)    0.67 ± 0.18   0.72 ± 0.24
 AUCinf (mcg/h*L)  231.97 ± 54.18 221.86 ± 68.10
 f (0-1)    0.41 ± 0.09   0.37 ± 0.09
 t1/2 (h)    1.97 ± 0.87   1.88 ± 1.02
 Cl/F (L/h/kg)    1.21 ± 0.27   1.34 ± 0.51
    
Total captopril Cmax (ng/mL)    614.93 ± 150.75   580.6 ± 135.0
 Tmax (h)    0.78 ± 0.24   0.94 ± 0.21
 AUCinf (mcg/h*L)  2171.23 ± 560.01 1987.20 ± 585.69
 f (0-1)    0.16 ± 0.03   0.14 ± 0.03
 t1/2 (h)    2.95 ± 0.36   2.93 ± 0.27
 Cl/F (L/h/kg)    0.13 ± 0.03   0.14 ± 0.03
Cmax, maximum plasma concentration; Tmax, time to maximum plasma concentration AUCinf, area under the plasma concentration versus time curve 
extrapolated to infinity; f (0-1), ratio of AUC0-1/AUCinf; t1/2, half-life; Cl/F, oral clearance (L/h/kg).
aValues are mean ± SD. P > .05 for all parameters when captopril alone is compared with captopril with cephradine.
Figure 2.  Cephradine plasma concentration versus time curves. 
Data represent mean ± SD for each time point. , cephradine 
alone; , cephradine with captopril.
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part, by the kidneys through glomerular filtration 
and tubular secretion.33,34 Although competition for 
renal re-absorption by means of renal transporters 
(eg, hPEPT1 and hPEPT2) could increase the renal 
clearance of the substrates when co-administered, 
there was no evidence of this in the present study.
Our hypothesis, that cephradine and captopril 
may compete for peptide transporters, was based on 
several prior observations. Cephradine is transported 
by means of hPEPT1 in cultured human intestinal 
cell monolayers, a process that is inhibited by oli-
gopeptides and peptidomimetics.19,24,35 Intestinal 
perfusion studies in animals and studies using iso-
lated intestinal membrane vesicles have demon-
strated that ACE inhibitors are also transported 
by means of peptide transporters, and that their 
transport is competitively inhibited by oligopeptides 
and peptidomimetics, including cephalosporins.20–22 
Similarly, in vitro investigations have described the 
saturable transport of ACE inhibitors by the renal 
peptide transporters hPEPT1 and hPEPT2.14 Jacolot 
and colleagues demonstrated that intra-intestinal 
administration of captopril in rats causes a marked 
increase in the half-life of the cephalosporin cefdinir.36 
In a subsequent experiment, the same group admin-
istered cephalexin (a cephalosporin) and quinapril 
(an ACE inhibitor) to rats, using different routes of 
administration (ie, oral and parenteral administra-
tion). They found that while parenteral administra-
tion of quinapril did not alter the disposition of 
either orally or parenterally administered cephalexin, 
the co-administration of oral cephalexin and oral 
quinapril resulted in a 30% decrease in cephalexin oral 
clearance and a 30% increase in cephalexin AUC.37 
They also observed a decrease in the cephalexin 
absorption rate constant with oral quinapril, but no 
difference in the extent of absorption. They sug-
gested that competition of cephalosporins and ACE 
inhibitors for active tubular secretion in the kidneys 
by means of a renal anionic transport system, as well 
as inhibition of active transport of cephalexin by 
quinapril in the intestine may be responsible for the 
observed pharmacokinetic behavior.16,38,39 
Despite in vitro and animal studies suggesting the 
possibility of a significant interaction between 
cephradine and captopril, there are several plausible 
explanations for the lack of such an interaction in 
the current study. Based on the variability in our 
data, the number of subjects required to detect a 
30% decrease in total captopril AUC when coadmin-
istered with cephradine is 8 (with a power of 80% 
and α = .05). The corresponding sample size calcula-
tion to detect a 30% decrease in cephradine AUC 
when coadministered with captopril is 9. Therefore, 
we believe our study was adequately powered to 
detect what we consider clinically important differ-
ences. Although total captopril concentrations were 
still detectible in plasma samples at the end of our 
sampling strategy (10 hours), we do not believe this 
affected our ability to detect a potential interaction, 
as the primary mechanism of a potential interaction 
is likely to involve changes in absorption, which 
would be characterized by our sampling. Moreover, 
our sampling captured almost 90% of the total cap-
topril AUC. Importantly, it is likely that multiple 
mechanisms are responsible for cephradine and 
captopril absorption in vivo, so that inhibition of a 
Table II  Cephradine Pharmacokinetic Parameters 
From Noncompartmental Analysisa
 Cephradine  Cephradine  
Parameter Alone With Captopril
Cmax (mg/L) 23.33 ± 8.28 20.25 ± 5.33
Tmax (h) 0.917 ± 0.375 1.00 ± 0.280
AUCinf (mg/h*L) 35.49 ± 8.87 34.66 ± 11.12
f (0-1) 0.31 ± 0.17 0.27 ± 0.14
t1/2 (h) 1.26 ± 0.76 1.31 ± 1.75
Cl/F (L/h/kg) 0.2 ± 0.05 0.2 ± 0.06 
Cmax, maximum plasma concentration; Tmax, time to maximum plasma 
concentration AUCinf, area under the plasma concentration versus time 
curve extrapolated to infinity; f (0-1), ratio of AUC0-1/AUCinf; t1/2, half-
life; Cl/F, oral clearance (L/h/kg).
aValues are mean ± SD. P > .05 for all parameters when captopril alone 
is compared with captopril with cephradine.
Figure 3.  Change in cephradine Cmax (maximum plasma 
cephradine concentration). Lines represent individual sub-
ject changes.
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single route of permeation or single transporter (or 
even a single family of transporters), has a diluted 
effect. This phenomenon likely includes both active 
and passive transport mechanisms. For example, we 
demonstrated that the in vivo intestinal permeabil-
ity of valacyclovir, a well known hPEPT1 substrate, 
correlates well with the intestinal expression of the 
transporter, HPT1, whereas correlation with hPEPT1 
is poor.40 The role of HPT1 in the transport of other 
hPEPT1 substrates is currently under investigation; 
however, it is reasonable to speculate that there is 
inherent redundancy in peptide transporters. In this 
regard, it is interesting to note a recent study con-
ducted to examine the potential for cephalexin- 
valacyclovir interactions in human subjects after 
oral co-administration of valacyclovir and cephalexin. 
The authors reported that co-administration of vala-
cyclovir and cephalexin minimally affected the AUC 
of the parent drug acyclovir, suggesting minimal 
interaction between these hPEPT1 substrates.41 The 
authors indicate that the lack of interaction may sug-
gest the possibility that cephalexin and valacyclovir 
are absorbed by means of other transporters and are 
less dependent on hPEPT1-mediated transport than 
previously suggested.41 It is also pertinent to note 
that transporter expression and distribution may be 
quite different in humans compared with animals 
and in vitro models.
Another factor that could explain the lack of 
interaction between cephradine and captopril is that 
the doses used may have been insufficient to satu-
rate the existing transporters in vivo. The doses were 
chosen based on typical clinical doses of the 2 drugs. 
However, the Michaelis-Menton constants (km) for 
cephradine and captopril absorption have been 
reported as 1.50 mM and 5.91 mM, respectively.42 
Although it is difficult to accurately estimate the 
precise volume in which an oral dosage form would 
be dissolved in vivo, the 500-mg dose of cephradine 
and the 25-mg dose of captopril corresponds to 
molar amounts of approximately 1.43 and 0.12 
mmol, respectively. It is therefore quite possible that 
the concentrations of the drugs present in the intes-
tinal lumen may have been substantially lower than 
those required to saturate the peptide transporter-
mediated absorption process. Study drugs were 
administered in the fasted state, without standardi-
zation of prior dietary protein intake. Theoretically, 
this may have influenced our results. For example, 
studies conducted in rats indicate fasting for 24–48 
hours may increase intestinal PEPT1 expression; it 
is unknown, however, whether this phenomenon 
occurs in humans, and, if so, whether the brief fast 
used in the present study (10 hours) would suffi-
ciently impact hPEPT1 expression.43,44 Additionally, 
animal studies have suggested that high protein 
diets may result in increased expression of PEPT1, 
although this finding has not yet been confirmed in 
humans.45–47
The drugs used in this study, cephradine and cap-
topril were not chosen because of any perceived 
likelihood that these compounds would be com-
monly coadministered clinically; rather, they were 
selected as representative substrates for aminoc-
ephalosporins and ACE inhibitors, respectively. To 
this end, captopril and cephradine are both well 
characterized PEPT1 substrates that have been 
shown to compete for PEPT1 (in both in vitro and 
animal experiments).48,49 Captopril also offered a 
practical advantage over other ACE inhibitors, 
because of its relatively short half-life (ie, this may 
limit the duration of any hypotensive effects in 
study subjects). It is unknown whether choosing 
alternative ACE inhibitor and cephalosporin sub-
strates would produce similar results.
CONCLUSIONS
To the best of our knowledge, this is the first study 
examining the potential interaction between cepha-
losporins and ACE inhibitors in humans. In summary, 
co-administration of 2 peptidomimetic compounds, 
cephradine and captopril, did not result in clinically 
significant changes in the pharmacokinetics of 
cephradine or captopril, despite sharing common 
transport pathways in the small intestine and kid-
neys. Based on these results, co-administration of 
these hPEPT1 and hPEPT2 substrates is not likely to 
result in clinically important drug interactions; 
although it is unknown whether this conclusion can 
be generalized to other hPEPT1/hPEPT2 substrates, 
other studies support this premise. This apparent 
lack of propensity for transport-related drug interac-
tions offers further support for the use of hPEPT1-
mediated transport as a means of improving oral 
drug absorption.
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